AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24763755 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids administered earlier in patients with no topical antibiotic use before enrollment
Number of subjects: 0
Study 22426307 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/day
Number of subjects: 623
Study 22426307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study 20097461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (RAS inhibitors [ACE inhibitors plus ARBs] plus high‐dose statin and spironolactone)
Number of subjects: 128
Study 20097461 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (ACE inhibitors with low‐dose statin)
Number of subjects: 128
Study 20097461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 128
Study 18247193 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg)
Number of subjects: 60
Study 18247193 — intervention group
Group type: COMPARATOR
Intervention: Eicosapentaenoic acid (EPA, 1000 mg)
Number of subjects: 60
Study 18247193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EPA and fluoxetine
Number of subjects: 60
Study 15865119 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater seal device
Number of subjects: 55
Study 15865119 — intervention group
Group type: COMPARATOR
Intervention: Flutter valve drainage bag
Number of subjects: 55
Study 14989113 — intervention group
Group type: EXPERIMENTAL
Intervention: Depigmented, polymerized extract of D. pteronyssinus and D. farinae
Number of subjects: 22
Study 14989113 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacological treatment only)
Number of subjects: 22
Study 10637145 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a flap of pectineus fascia
Number of subjects: 37
Study 10637145 — intervention group
Group type: COMPARATOR
Intervention: No flap of pectineus fascia (control)
Number of subjects: 37
Study 8701396 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 3 g daily
Number of subjects: 40
Study 8701396 — intervention group
Group type: COMPARATOR
Intervention: corn oil (placebo)
Number of subjects: 40
Study 1521779 — intervention group
Group type: EXPERIMENTAL
Intervention: Gc phenotype
Number of subjects: 258
Study 1521779 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSG phenotype
Number of subjects: 258
Study 6430310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.3 mg i.m. followed by 0.4 mg every 6 h for 3 days)
Number of subjects: 80
Study 6430310 — intervention group
Group type: COMPARATOR
Intervention: Intermittent morphine (10 mg i.m.)
Number of subjects: 80
Study 6430310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 80
Study 6430310 — intervention group
Group type: COMPARATOR
Intervention: Intermittent morphine
Number of subjects: 80
Study 31204885 — intervention group
Group type: EXPERIMENTAL
Intervention: Male contraceptive pill willingness
Number of subjects: 412
Study 29193165 — intervention group
Group type: EXPERIMENTAL
Intervention: FX CorDiax dialyzer
Number of subjects: 10
Study 29193165 — intervention group
Group type: COMPARATOR
Intervention: FX dialyzer
Number of subjects: 10
Study 27505962 — intervention group
Group type: EXPERIMENTAL
Intervention: Seat fixed rotation manipulation (Group A)
Number of subjects: 170
Study 27505962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position rotation manipulation (Group B)
Number of subjects: 170
Study 27505962 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position rotation manipulation (Group C)
Number of subjects: 170
Study 24270192 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up by repeat cytology in primary care after initial BNA result, first test due 6 months after initial result.
Number of subjects: 621
Study 24270192 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant anxiety at recruitment, pain after follow-up cytology, having children, dissatisfaction with support received after initial BNA test.
Number of subjects: 621
Study 22864310 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory recognition test with previously unseen stimuli (fillers)
Number of subjects: 2
Study 22864310 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory recognition test with previously seen stimuli (targets)
Number of subjects: 2
Study 22864310 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with low scores on a social avoidance measure
Number of subjects: 2
Study 22864310 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory for negative stimuli
Number of subjects: 2
Study 22864310 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus valence
Number of subjects: 2
Study 20397454 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 65
Study 20397454 — intervention group
Group type: COMPARATOR
Intervention: Inositol (control)
Number of subjects: 65
Study 17113190 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous etanercept therapy (50 mg once weekly)
Number of subjects: 2546
Study 17113190 — intervention group
Group type: COMPARATOR
Intervention: Interrupted etanercept therapy (50 mg once weekly)
Number of subjects: 2546
Study 17113190 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous etanercept therapy
Number of subjects: 2546
Study 17113190 — intervention group
Group type: COMPARATOR
Intervention: Interrupted etanercept therapy
Number of subjects: 2546
Study 16298925 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer desktop‐based Virtual Reality (VR) street crossing training
Number of subjects: 19
Study 16298925 — intervention group
Group type: COMPARATOR
Intervention: Computer based visual scanning tasks (Control)
Number of subjects: 19
Study 12009350 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot GnRH agonist followed by 17beta-estradiol transdermal patches (100 to 300 microg for at least 12 days)
Number of subjects: 296
Study 12009350 — intervention group
Group type: COMPARATOR
Intervention: Endometrial preparation starting on day 1 of menstrual cycle with 200 microg increasing to 300 microg after 7 days
Number of subjects: 296
Study 9657086 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist weight exercise (WW; n = 12)
Number of subjects: 23
Study 9657086 — intervention group
Group type: EXPERIMENTAL
Intervention: No-wrist weight exercise (NW; n = 11)
Number of subjects: 23
Study 9657086 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (NE; n = 11)
Number of subjects: 23
Study 7609299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 10 mg
Number of subjects: 52
Study 7609299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pirenzepine 10 mg and famotidine 20 mg
Number of subjects: 52
Study 2146229 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator
Number of subjects: 26
Study 2146229 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenator
Number of subjects: 26
Study 2146229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid oxygenator
Number of subjects: 26
Study 2146229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow fibre oxygenator
Number of subjects: 26
Study 2146229 — intervention group
Group type: COMPARATOR
Intervention: All oxygenators
Number of subjects: 26
Study 326594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone 17,21-dipropionate cream
Number of subjects: 36
Study 326594 — intervention group
Group type: COMPARATOR
Intervention: 0.05% clobetasol propionate cream
Number of subjects: 36
Study 31964428 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato-based side dish
Number of subjects: 50
Study 31964428 — intervention group
Group type: COMPARATOR
Intervention: Refined grain-based side dish
Number of subjects: 50
Study 30519776 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback using a 'balance' belt worn around the waist for 1 month in daily life.
Number of subjects: 39
Study 30519776 — intervention group
Group type: EXPERIMENTAL
Intervention: Preselection trial of the 'balance' belt for 2 hours in the hospital.
Number of subjects: 39
Study 30519776 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 39
Study 28276741 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention (Kanker Nazorg Wijzer)
Number of subjects: 462
Study 28276741 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 462
Study 25986136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hospital-based care transition intervention
Number of subjects: 700
Study 25986136 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study 23040657 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant AKI (AKI stage 2 or 3)
Number of subjects: 218
Study 23040657 — intervention group
Group type: COMPARATOR
Intervention: No AKI (AKI stage 0 or 1)
Number of subjects: 218
Study 23040657 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI group
Number of subjects: 218
Study 22185726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esmolol infusion
Number of subjects: 40
Study 22185726 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 40
Study 19061198 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing BOF before completing questionnaires
Number of subjects: 39
Study 19061198 — intervention group
Group type: COMPARATOR
Intervention: Viewing BOF after completing questionnaires
Number of subjects: 39
Study 19061198 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing BOF after completing questionnaires (physicians)
Number of subjects: 39
Study 19061198 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing BOF (all participants)
Number of subjects: 39
Study 16310929 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial IFN-alpha for 8 weeks (2 weeks 5x3x10(6)IU/wk; 2 weeks 5x6x10(6)IU/wk; 2 weeks 5x9x10(6)IU/wk; 2 weeks 3x9x10(6)IU/wk)
Number of subjects: 16
Study 16310929 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha maintenance at 3x9x10(6)IU/wk after nephrectomy
Number of subjects: 16
Study 16310929 — intervention group
Group type: COMPARATOR
Intervention: No intervention (progressive disease)
Number of subjects: 16
Study 12775347 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative EEG analysis (q-EEG) in OCD patients
Number of subjects: 0
Study 12775347 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative EEG analysis (q-EEG) in OCD patients with higher scores in doubting test
Number of subjects: 0
Study 12775347 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative EEG analysis (q-EEG) in severely ill OCD patients
Number of subjects: 0
Study 11039921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dawn signals (average illuminance 155 lux)
Number of subjects: 9
Study 11039921 — intervention group
Group type: COMPARATOR
Intervention: Control light (0.1 lux)
Number of subjects: 9
Study 9109702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 50 micrograms
Number of subjects: 342
Study 9109702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms
Number of subjects: 342
Study 9109702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 micrograms
Number of subjects: 342
Study 9109702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 9109702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (all doses)
Number of subjects: 342
Study 8464394 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms nocloprost (solved in 50 cc water)
Number of subjects: 6
Study 8464394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3096261 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 14
Study 3096261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TPN)
Number of subjects: 14
Study 3096261 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN
Number of subjects: 14
Study 30856111 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high comorbidity
Number of subjects: 362
Study 30856111 — intervention group
Group type: EXPERIMENTAL
Intervention: Each further comorbidity
Number of subjects: 362
Study 30856111 — intervention group
Group type: COMPARATOR
Intervention: High comorbidity
Number of subjects: 362
Study 30856111 — intervention group
Group type: COMPARATOR
Intervention: Low comorbidity
Number of subjects: 362
Study 28954544 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (social cognitive theory intervention)
Number of subjects: 57
Study 28954544 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyles intervention (knowledge-based intervention)
Number of subjects: 57
Study 27282308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap harvesting and pericostal no‐compression 'edge' suture (IMF group)
Number of subjects: 297
Study 27282308 — intervention group
Group type: COMPARATOR
Intervention: Standard suture technique with intrapleural intercostal nerve block (IINB group)
Number of subjects: 297
Study 24219814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin 300 mg twice a day (TNS)
Number of subjects: 20
Study 24219814 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tobramycin (IV)
Number of subjects: 20
Study 24219814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin (TNS)
Number of subjects: 20
Study 24219814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study 21979491 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus rhamnosus LPR and Bifidobacterium longum BL999) in Finnish infants
Number of subjects: 162
Study 21979491 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in Finnish infants
Number of subjects: 162
Study 21979491 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment in German infants
Number of subjects: 162
Study 21979491 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants (control group)
Number of subjects: 162
Study 20880093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 20
Study 20880093 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 20
Study 18926162 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose/insulin infusion
Number of subjects: 12
Study 18926162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid plus heparin infusion
Number of subjects: 12
Study 18926162 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 15894970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 4623
Study 15894970 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 4623
Study 15894970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban and Abciximab
Number of subjects: 4623
Study 12360590 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP-therapy (REMstar Choice, Respironics, USA)
Number of subjects: 12
Study 12360590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nasal mask without turning on the apparatus)
Number of subjects: 12
Study 10195548 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60
Study 10195548 — intervention group
Group type: COMPARATOR
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 60
Study 7782140 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 7782140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2101170 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release naproxen (750 mg/day for 10-15 days)
Number of subjects: 48
Study 2101170 — intervention group
Group type: COMPARATOR
Intervention: Standard naproxen (two 375 mg/day capsules for 10-15 days)
Number of subjects: 48
Study 2101170 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release naproxen
Number of subjects: 48
Study 2101170 — intervention group
Group type: COMPARATOR
Intervention: Standard naproxen
Number of subjects: 48
Study 10249458 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis intervention (two different intensities)
Number of subjects: 30
Study 10249458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 30041568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-methods (MM; PACKS and SLURRY concurrently)
Number of subjects: 8
Study 30041568 — intervention group
Group type: COMPARATOR
Intervention: Ice slurry ingestion (SLURRY)
Number of subjects: 8
Study 30041568 — intervention group
Group type: COMPARATOR
Intervention: Ice-packs placed on the quadriceps and hamstrings (PACKS)
Number of subjects: 8
Study 30041568 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 8
Study 28564557 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg orally twice daily)
Number of subjects: 142
Study 28564557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 27180352 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step self-etch adhesive (1-SEA)
Number of subjects: 200
Study 27180352 — intervention group
Group type: COMPARATOR
Intervention: 3-step etch-and-rinse adhesive (3-E&RA)
Number of subjects: 200
Study 23742202 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicalized counseling video (by an endocrinologist)
Number of subjects: 89
Study 23742202 — intervention group
Group type: COMPARATOR
Intervention: Demedicalized counseling video (by a psychologist)
Number of subjects: 89
Study 21848448 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B) injections on one side of the face
Number of subjects: 15
Study 21848448 — intervention group
Group type: COMPARATOR
Intervention: Saline control injections on the other side of the face
Number of subjects: 15
Study 21848448 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall self-assessment and objective mexameter evaluation
Number of subjects: 15
Study 19135077 — intervention group
Group type: COMPARATOR
Intervention: Composite paradigm intervention for face processing
Number of subjects: 0
Study 17244149 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin coating with Clearfil Protect Bond (PB) and Protect Liner F (PLF)
Number of subjects: 5
Study 17244149 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite restorations with PB
Number of subjects: 5
Study 17244149 — intervention group
Group type: COMPARATOR
Intervention: Control group with uncoated cavity surfaces
Number of subjects: 5
Study 14756461 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated timothy grass pollen extract
Number of subjects: 24
Study 14756461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11704311 — intervention group
Group type: COMPARATOR
Intervention: XRT
Number of subjects: 146
Study 11704311 — intervention group
Group type: EXPERIMENTAL
Intervention: A + XRT
Number of subjects: 146
Study 9144684 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) 175 mg/m2 followed by cisplatin 80 mg/m2
Number of subjects: 332
Study 9144684 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 80 mg/m2 followed by teniposide (Vumon) 100 mg/m2
Number of subjects: 332
Study 9144684 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/teniposide
Number of subjects: 332
Study 9144684 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 332
Study 9316683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (90 mg q.d.)
Number of subjects: 66
Study 9316683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9316683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 66
Study 3234468 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg
Number of subjects: 12
Study 3234468 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg with Diazepam 10 mg
Number of subjects: 12
Study 3234468 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 3234468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31092019 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dipper group (systolic BP decline <10%)
Number of subjects: 449
Study 31092019 — intervention group
Group type: COMPARATOR
Intervention: Dipper-dipper group (systolic BP decline 10% or more)
Number of subjects: 449
Study 28550377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Number of subjects: 91
Study 28550377 — intervention group
Group type: COMPARATOR
Intervention: Hydroxycellulose (HEC) placebo gel
Number of subjects: 91
Study 27871242 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy for 12 months
Number of subjects: 69
Study 25183661 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate modified-release long-acting formulation (MPH-LA) at 20 mg/day, up-titrated to 40-80 mg/day
Number of subjects: 298
Study 25183661 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate modified-release long-acting formulation (MPH-LA)
Number of subjects: 298
Study 23169362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400mg/day for 6 months
Number of subjects: 100
Study 23169362 — intervention group
Group type: COMPARATOR
Intervention: Losartan and enalapril (Control)
Number of subjects: 100
Study 20808923 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine & Artesunate (AS+AQ) monthly
Number of subjects: 2451
Study 20808923 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine & Artesunate (AS+AQ) bimonthly
Number of subjects: 2451
Study 20808923 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-Pyrimethamine (SP) bimonthly
Number of subjects: 2451
Study 20808923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2451
Study 17511193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone gel
Number of subjects: 100
Study 17511193 — intervention group
Group type: COMPARATOR
Intervention: KY gel
Number of subjects: 100
Study 16014845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (DEC/ALB)
Number of subjects: 0
Study 16014845 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (ALB)
Number of subjects: 0